Market Overview

ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference

ImmunoGen (NASDAQ: IMGN) today announced the presentation of
interim data from the ongoing Phase I trial of Sanofi's SAR566658 at the
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics meeting (abstract #A73) being held in Boston. SAR566658 is
an ADC targeted to CA6, which is found on many cases of ovarian, breast,
and other epithelial cancers. The data reported support that SAR566658
is generally well tolerated and can induce objective responses and
sustained stable disease in heavily pretreated patients with
CA6-positive cancers.

SAR566658 was created by ImmunoGen and licensed preclinically to Sanofi
as part of a broader collaboration between the companies. It comprises
the Company's huDS6 CA6-targeting antibody with one of ImmunoGen's

See full press release

Posted-In: Earnings News Guidance Global

 

Most Popular

Related Articles (IMGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free